APA aipamena

Moore, M. C., Smith, M. S., Sinha, V. P., Beals, J. M., Michael, M. D., Jacober, S. J., & Cherrington, A. D. (2014). Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism. Diabetes.

Chicago Style aipamena

Moore, Mary Courtney, Marta S. Smith, Vikram P. Sinha, John M. Beals, M. Dodson Michael, Scott J. Jacober, and Alan D. Cherrington. "Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect On Glucose Metabolism." Diabetes 2014.

MLA aipamena

Moore, Mary Courtney, et al. "Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect On Glucose Metabolism." Diabetes 2014.

Kontuz: berrikusi erreferentzia hauek erabili aurretik.